Dare Bioscience, Inc. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On July 13, 2026, Dare Bioscience received notice of failure to satisfy continued listing standards, triggering Item 3.01 disclosure of delisting risk or transfer of listing. No specific listing rule violation, remediation timeline, or details on which exchange are provided in the available filing text. The company trades at ~$21.3M market value.
Why this rating
Delisting notice is existential threat to public company; eliminates NASDAQ/NYSE access, sharply increases capital costs, damages credibility and investor base.
Extracted items
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.